178 related articles for article (PubMed ID: 1311352)
1. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants.
Bailey TC; Trulock EP; Ettinger NA; Storch GA; Cooper JD; Powderly WG
J Infect Dis; 1992 Mar; 165(3):548-52. PubMed ID: 1311352
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
[TBL] [Abstract][Full Text] [Related]
3. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
5. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
Martin M; Mañez R; Linden P; Estores D; Torre-Cisneros J; Kusne S; Ondick L; Ptachcinski R; Irish W; Kisor D
Transplantation; 1994 Oct; 58(7):779-85. PubMed ID: 7940710
[TBL] [Abstract][Full Text] [Related]
8. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
[TBL] [Abstract][Full Text] [Related]
10. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
11. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
13. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis.
Boivin G; Erice A; Crane DD; Dunn DL; Balfour HH
J Infect Dis; 1993 Aug; 168(2):332-5. PubMed ID: 8393055
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir.
Brumble LM; Milstone AP; Loyd JE; Ely EW; Pierson RN; Gautam S; Dummer JS
Chest; 2002 Feb; 121(2):407-14. PubMed ID: 11834650
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.
Johanssson I; Mårtensson G; Andersson R
Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
